Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. Patients received rituximab plus bendamustine or rituximab plus chlorambucil every four weeks for six cycles. Rituximab plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Michallet, Anne-Sophie, Aktan, Melih, Hiddemann, Wolfgang, Ilhan, Osman, Johansson, Peter, Laribi, Kamel, Meddeb, Balkis, Moreno, Carol, Raposo, João, Schuh, Anna, Ünal, Ali, Widenius, Tom, Bernhardt, Alf, Kellershohn, Kerstin, Messeri, Dimitri, Osborne, Stuart, Leblond, Véronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865431/
https://www.ncbi.nlm.nih.gov/pubmed/29419437
http://dx.doi.org/10.3324/haematol.2017.170480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865431/
https://www.ncbi.nlm.nih.gov/pubmed/29419437
http://dx.doi.org/10.3324/haematol.2017.170480

Ejemplares similares